Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target? - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Biochimica et Biophysica Acta (BBA) - Reviews on Cancer Année : 2021

Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

Résumé

Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers. We propose to evaluate the various pathologies in which the metalloprotease-cleaved CD95L is accumulated and analyze whether this soluble ligand may play a significant role in the pathology progression. Based on the TNFα-targeting therapeutics, we envision that targeting the soluble form of CD95L may represent a very attractive therapeutic option in the pathologies depicted herein.

Domaines

Chimie Cancer
Fichier principal
Vignette du fichier
Kurma et al - 2021 - Soluble CD95L in cancers and chronic inflammatory disorders.pdf (6.96 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03333846 , version 1 (16-09-2021)

Identifiants

Citer

Keerthi Kurma, Andrea Boizard-Moracchini, Gael Galli, Mickael Jean, Pierre Vacher, et al.. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021, 1876 (2), pp.188596. ⟨10.1016/j.bbcan.2021.188596⟩. ⟨hal-03333846⟩
170 Consultations
324 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More